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Background: The initial treatment of obsessive–compulsive disorder (OCD) has generally been limited to sero-
tonergic agents, cognitive-behavioral therapy (CBT), or a combination of the two. These findings were supported by
the POTS study for OCD in children and adolescents. However, treatment with serotonergic agents or CBT can take
several weeks before benefit is seen; severe cases of OCD may require more immediate treatment. Case report: The
authors present a case of severe OCD in an adolescent that required immediate treatment due to her critical medical
condition. The patient’s symptoms included not eating or taking medications or fluids by mouth due to fears of con-
tamination. A medical hospitalization was previously required due to dehydration. As treatment with an SSRI would
not have quick enough onset and the patient was initially resistant to participating in CBT, the patient was psychiatri-
cally hospitalized and first started on liquid risperidone. After several doses of risperidone, the patient was able to
participate in CBT and start sertraline. Discussion: The authors discuss the differential diagnosis of such a patient, in-
cluding the continuum of OCD symptoms and psychotic symptoms. The authors discuss the different treatment op-
tions, including the utilization of inpatient psychiatric hospitalization. The authors discuss the potential risks and
benefits of using atypical antipsychotics in lieu of benzodiazepines for the initial treatment of severe adolescent
OCD. The authors also discuss other current treatment recommendations and rationale for the treatment that was pur-
sued. Conclusions: This patient received benefit of her symptoms relatively quickly with psychiatric hospitalization
and an atypical antipsychotic. The diagnosis of a psychotic disorder should be considered. These treatment options
must be weighed against the risks of atypical antipsychotics, including extrapyramidal symptoms, weight gain, and
metabolic syndrome; benzodiazepines also have their risks and benefits. Additionally, the cost of time and finances
of inpatient hospitalization must be considered. More research is needed regarding the short- and long-term efficacy
and safety of antipsychotics in the treatment of OCD in the child and adolescent population.
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INTRODUCTION
The treatment for obsessive–compulsive disorder (OCD) in
the child and adolescent population has been varied. The Pe-
diatric OCD Treatment Study (POTS, 2004) suggests effec-
tiveness for Cognitive Behavior Therapy (CBT) whereas
four medications have received FDA approval for the treat-
ment of OCD: fluoxetine for ages 7 and above, fluvoxamine
for ages 8 and above, sertraline for ages 6 and above and
clomipramine for ages 10 and above (POTS, 2004). These
treatments are usually applied in the outpatient setting, with
an adequate trial consisting of 8–12 weeks (POTS, 2004).
However, these treatments usually take several weeks to
achieve full effect (Bloch et al., 2006). In some extremely
severe cases it may be necessary to achieve benefit sooner.
CASE STUDY
One such case was “Amy”, a 14-year-old Caucasian girl
with a three-year history of fear of contamination with pin-
worms from holding her hands too close to her mouth. She
was also concerned about contamination from contact with
her mother and the family dogs and concerned that she
would contaminate her mother with physical contact. She
constantly washed her hands to avoid contamination. Amy’s
fears of contamination had progressed to the point she would
avoid opening her mouth to speak, and she had gone 10
months with her essentially not talking. Her diet was re-
duced to chocolate milk and wheat thin crackers. She devel-
oped elaborate rituals for opening containers, which in-
volved her spilling some amount of food/liquid onto the
floor to avoid consuming particles that had been exposed to
air. If the ritual was not exact, she would discard the entire
container. She began to have a very rapid decline and
“stopped eating” for a period of 4 weeks, which led to an in-
patient psychiatric admission. This hospitalization proved
fruitless, and Amy was eventually presented to the emer-
gency department due to dehydration. She was initially
admitted to the pediatric service for medical stabilization
with IV fluids and was subsequently transferred to Child
Psychiatry.
On the first day of psychiatric hospitalization, Amy
woke up with debilitating anxiety and refused to eat or even
open her mouth. She initially refused oral medications, but
her anxiety spurred her to take an initial dose of risperidone
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0.13 mg in liquid form. An additional 0.13 mg of liquid
risperidone PO was ordered, which she took, but she still re-
fused to drink water or eat food, stating she would “rather
die”. A behavioral plan was discussed, but Amy resisted any
level of exposure therapy during the first day. She was coop-
erative with risperidone 0.13 mg liquid TID. Within four
hours of the second dose on hospital day 2 (fourth dose to-
tal), she drank Gatorade with staff assistance and began ac-
cepting heightened levels of exposure therapy. Later that
day, she was able to eat a small yogurt with staff assistance.
On hospital day 3, Amy was able to eat without assistance
and ate granola bars. She was started on sertraline 12.5 mg
daily, and she was still eating in a ritualistic fashion in order
to keep her hands as far from her mouth as possible. During
this time, she was not performing activities of daily living
such as basic personal hygiene. Each day, Amy was exposed
to greater levels of exposure therapy. By the end of her
10-day hospitalization, Amy was taking risperidone 0.13 mg
TID and sertraline 50 mg daily. At the time of discharge, she
was talking in an appropriate fashion, eating more appropri-
ate foods using her hands, and her contamination fears sig-
nificantly diminished.
DISCUSSION
Amy presented an extraordinary case of OCD. The patient
was initially resistant to participating in CBT, and an SSRI
would have taken weeks to have effect. Due to the potential
for medical danger and the severity of symptoms, the patient
was admitted to an inpatient Child and Adolescent Psychiat-
ric facility. An antipsychotic was used initially, and an SSRI
was then added; the patient was eventually able to partici-
pate in CBT with improvement, and the patient was dis-
charged with improvement in symptoms and functioning.
We will address each of these treatment modalities.
Inpatient hospitalization
There is sparse quality research regarding the utility of inpa-
tient psychiatric hospitalization in treating obsessive–com-
pulsive disorder in the child and adolescent population. A
literature search suggests that inpatient hospitalization is
rarely used as a treatment modality for OCD (Shoval,
Zalsman, Sher, Apter & Weizman, 2006), and is usually re-
served for severe co-morbid conditions such as suicidality,
self-injury, violence or aggression, and severe eating disor-
ders such as anorexia nervosa (Shoval et al., 2006). How-
ever, some studies have shown a beneficial effect of a highly
structured environment offered by a milieu setting in treat-
ing adolescent OCD (Scahill, Walker, Lechner & Tynan,
1993). There are several advantages of treating adolescent
OCD in a residential or inpatient setting, including a con-
stant support system, greater time devoted to treatment, and
the presence of staff to minimize ritualistic and compulsive
behaviors (Björgvinsson et al., 2008). Constant staff super-
vision provides both added emotional support and dutiful
roadblocks to preventing ritualistic or compulsive behaviors
(Björgvinsson et al., 2008). Milieu treatment may also pro-
vide the opportunity to uncover maladaptive family accom-
modation of OCD symptoms and temporarily remove the
patient from these circumstances (Björgvinsson et al.,
2008). The inpatient setting also provides patients with a set-
ting where they can model after peers, which may increase
willingness to perform exposures (Björgvinsson et al.,
2008). However, a potential drawback to milieu treatment
may be the lack of being able to generalize treatment gains to
other setting, as treatment gains may prove transient when
the patient is discharged and parents are unable to provide
the same level of supervision in absence of milieu environ-
ment (Scahill et al., 1993). Undoubtedly, the milieu environ-
ment we provided and staff assistance, were crucial, in aid-
ing Amy in her treatment, as staff encouraged her to eat and
drink and to avoid her normal ritualistic behaviors. Addi-
tionally, there was the tangible benefit of discharge from the
facility pending her ability to conquer her cognitive distor-
tions and change her behavior, whereas she likely had less
motivation in her home environment, which may have been
compromised by family accommodations. Most studies in-
dicate that inpatient hospitalization for OCD hinges on
co-morbid conditions such as aggression or suicidality
(Scahill et al., 1993), but more research is indicated to
determine the utilization of the inpatient setting for treating
severe adolescent OCD in the absence of such other indica-
tors for hospitalization.
Risperidone
We feel the use of risperidone in the initial treatment of se-
vere adolescent OCD is one of the more unique aspects of
this case. Currently no antipsychotic is approved for the
treatment of OCD. Risperidone has previously been shown
to be successful as an augmenting agent in cases of refrac-
tory OCD in adults (McDougle, Epperson, Pelton, Wasylink
& Price, 2000) and adolescents (Thomsen, 2004). However,
it is not often considered for use as initial treatment, either as
a monotherapeutic or adjunct agent. The use of an anti-
psychotic as an anxiolytic is not a novel idea, as first genera-
tion antipsychotics have been referred to as “major tran-
quilizers” for their calming and sedating effects (Lorenz,
Jackson & Saitz, 2010). Subsequent to a randomized, dou-
ble-blind, placebo-controlled trial in 1986, the first-genera-
tion antipsychotic trifluoperazine was given FDA approval
for short-term treatment of generalized non-psychotic
anxiety (Gao, Muzina, Gajwani & Calabrese, 2006).
Specifically, antipsychotics may be beneficial in OCD,
which many have noted shares some features of a psychotic
or delusional process (Bellino, Patria, Ziero & Bogetto,
2005; Kozak & Foa, 1994; Rodowski, Cagande & Riddle,
2008). Patients with OCD have classically had insight into
the illogical nature of their thoughts or behaviors; the criteria
for OCD in the current version of the Diagnostic and Statisti-
cal Manual of Mental Disorders includes that the patient rec-
ognizes the obsessions or compulsions are excessive or un-
reasonable, although this does not apply to children
(DSM-IV-TR; APA, 2000). However, even with adult pa-
tients, clinical evidence suggests that not all patients with
OCD regard their symptoms as unreasonable or excessive.
The question, then, is if these fixed, false beliefs qualify
merely as obsessive thoughts, over-valued ideas, or are in
fact, delusion (Kozak & Foa, 1994). Studies of these “atypi-
cal obsessive–compulsives” indicate that these patients are
qualitatively different from patients with classical, insightful
OCD, with increased symptom severity, earlier onset of
symptoms, and greater likelihood to be refractory to treat-
ment (Bellino et al., 2005; Kozak & Foa, 1994). Since Amy
is a child, the DSM qualifier of requiring insight does not ap-
ply to making the diagnosis of OCD, yet the comparisons to
a psychotic process remain. Studies have suggested OCD
patients bordering on the psychotic may be the group most
responsive to antipsychotic augmentation (Rodowski et al.,
2008). Furthermore, there is some evidence to suggest that
some early cases of schizophrenia–spectrum disorders may
initially present with obsessive–compulsive symptoms, and
vice versa (Niendam, Berzak, Cannon & Bearden, 2009;
Rodowski et al., 2008; Tumkaya et al., 2009). Therefore,
this extreme case of OCD may be the precursor to a future
psychotic disorder, which may also account for the respon-
siveness to risperidone.
Benzodiazepines were historically the treatment of
choice for anxiety disorders, but with the advent of SSRIs,
their use has been limited to short-term periods of 2–4 weeks
due to risk of sedation, behavioral disinhibition, and poten-
tial for abuse, dependence, and tolerance (Nash & Nutt,
2005). Benzodiazepines carry the advantage of a rapid onset
of action, which may be beneficial in patients first starting an
SSRI or who cannot tolerate high doses of SSRIs (Hol-
lander, Kaplan & Stahl, 2003). Benzodiazepines also do not
carry the significant long-term side effects associated with
antipsychotics including weight gain, dystonia, extra-
pyramidal symptoms and metabolic syndrome. Although
several anecdotal and open-label studies have demonstrated
benzodiazepines to be useful in treating obsessive–compul-
sive disorder (Bodkin & White, 1989; Tesar & Jenike, 1984)
or anxiety disorders in children and adolescents (Biederman,
1990; Simeon & Ferguson, 1987), these findings have not
been consistently replicated when more structured studies
have been performed (Witek, Rojas, Alonso, Minami &
Silva, 2005). Two double-blind, placebo-controlled studies
failed to show that clonazepam was beneficial in treating
symptoms of OCD either as monotherapy (Hollander et al.,
2003) or in conjunction with sertraline (Crockett, Churchill
& Davidson, 2004). The use of benzodiazepines in the ado-
lescent population is also limited by sedation, the potential
for disinhibition and the potential for abuse or the develop-
ment of dependence (Reinblatt & Walkup, 2005). A
Cochrane review of pharmacotherapy for anxiety disorders
in children and adolescents did not recommend the use of
benzodiazepines due to lack of efficacy evidence, concerns
of dependency and treatment-emergent adverse events
(Ipser, Stein, Hawkridge & Hoppe, 2009). A review by
Grados and Riddle (2001) on the pharmacotherapy of child-
hood OCD recommended typical and atypical neuroleptics
as the first and second preferences, respectively, for
augmentation of treatment-refractory OCD; benzodiaze-
pines were the fifth preference.
Antipsychotics may be a useful alternative as they ap-
pear as effective as benzodiazepines in the treatment of anxi-
ety disorders; atypical antipsychotics significantly reduced
anxiety and were shown to be efficacious in treating refrac-
tory OCD and PTSD (Gao et al., 2006). In addition, the ac-
tion of atypical antipsychotics at the serotonergic receptors
may also prove protective of co-morbid mood disorders, as
it has long been felt that the serotonergic activity of the atyp-
ical antipsychotics may have some antidepressant properties
as well. However, antipsychotics do pose the risk of poten-
tially serious side effects of weight gain, diabetes, metabolic
syndrome and extrapyramidal symptoms. Ideally, both anti-
psychotics and benzodiazepines would serve a short-term
role in the treatment of OCD until the benefits of CBT and
SSRIs can take hold. There is some evidence that treatment
gains made through CBT while patients are on anti-
psychotics still hold after the antipsychotic has been tapered
off (Goldstein et al., 2009). On the contrary, there are con-
cerns that patients receiving both CBT and benzodiazepines
for anxiety disorders experience a loss of efficacy after the
benzodiazepine treatment is discontinued (Otto, Bruce &
Deckersbach, 2005; Westra, Stewart & Conrad, 2002). The
treatment team felt that Amy’s anxiety and “panic” were a
by-product of OCD, rather than actual panic disorder.
Therefore an antipsychotic was chosen rather than a benzo-
diazepine due to the limited evidence of benzodiazepine
proving effective for OCD and the likelihood that benefits
from CBT would hold after the medication was tapered off.
It is commonly held that the onset of anxiolytic effect
from SSRIs may take 4 to 6 weeks (Nash & Nutt, 2005). In
our case, we felt such a wait was not feasible due to the med-
ical acuity; her anxiety was preventing her from achieving
adequate nutrition. The action of atypical antipsychotics on
5-HT2A receptors would not explain the rapid anxiolytic
properties, nor would it explain the study and subsequent
FDA approval of a first-generation antipsychotic trifluope-
razine for the short-term treatment of anxiety (Mendels
et al., 1986). Although serotonin has long been thought to be
the key neurotransmitter involved in OCD, there are ample
sources citing the role of dopamine in the disorder (Denys,
Zohar & Westenberg, 2004; Westernberg, Fineberg &
Denys, 2007). Using animal models, Denys et al. (2004)
showed that potentiation of dopaminergic activity at D1 re-
ceptors produces obsessive–compulsive like behavior,
while D1 receptor antagonists reduce compulsive behaviors.
As dopamine is felt to be an important modulator in the con-
ditioned fear response (Pezze & Feldon, 2004), the anti-
dopaminergic activity of typical and atypical antipsychotics
may also decrease this fear response, which may be particu-
larly relevant in OCD (Pezze & Feldon, 2004). Specifically,
one study found that D1 dopamine receptors are involved in
danger recognition, and D2 receptors are involved in setting
up adaptive responses to cope with potentially threatening
stimuli (Perez de la Mora, Gallegos-Cari, Arizmendi-Gar-
cia, Marcellino & Fuxe, 2010). One extrapolation from this
information is that D1 receptors may modulate the “obses-
sion” component of OCD, and D2 receptors may modulate
the “compulsion” component. Thus, administration of a po-
tent D2-antagonist such as risperidone might understand-
ably lead to a reduction in compensatory compulsions in
OCD. This may help to explain the finding that dopamine
antagonists play a more significant role in OCD compared
with other anxiety disorders (Decloedt & Stein, 2010). How-
ever, there remain inconsistencies in the literature regarding
the efficacy of antidopaminergic agents in treating OCD,
specifically the fact that substantial treatment benefits are
enhanced when antipsychotics augment SSRI treatment
compared to antipsychotic monotherapy (Westernberg et al.,
2007). Although it may not be entirely clear, there seems to
be an important role of the dopaminergic system in the
pathophysiology and treatment of OCD (Denys et al., 2004;
Westenberg et al., 2007).
In our case, Amy was able to start drinking and eating,
resisting her compulsive behaviors, after only a few doses of
risperidone. It also appears that D2-antagonism has a
quicker onset of action than the 5-HT2A antagonism/5-HT1A
agonism in providing relief of anxiety. In the initial
trifluoperazine study, trifluoperazine separated from pla-
cebo in efficacy and statistical significance within the first
week, and continued through the full 4 weeks of the study
(Mendels et al., 1986). This timeframe is similar to that for
using antipsychotics in treating delirium, a condition in
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which antipsychotics are considered the mainstay, as suc-
cessful treatment can be achieved between 7 and 28 days
(Attard, Ranjith & Taylor, 2008). A known advantage of
augmentation with an antipsychotic rather than initiating a
trial of another monotherapeutic agent such as an SSRI is
that only a 4-week trial is needed for augmentation, whereas
another 10- to 12-week trial would be necessary for the trial
of the monotherapeutic agent (Dougherty, Rauch & Jenike,
2004).
There is little research discussing the efficacy of anti-
psychotics used as initial therapy or monotherapy for OCD
in general, let alone in children and adolescents. Most stud-
ies herald the usefulness of antipsychotics as an augmenting
agent to SSRIs (Masi et al., 2009). One study showed that
over half of children who received an atypical antipsychotic
as an augmenting strategy for OCD showed improvement
(Masi et al., 2009). In adults with treatment-refractory OCD,
antipsychotics have the largest body of evidence supporting
their use as augmenting agents (Decloedt & Stein, 2010).
Sertraline
Sertraline is approved by the FDA for treating OCD in adults
and children ages 6 and older (POTS, 2004). It is well
known that SSRIs work rather slowly and can take as much
as 6–12 weeks to exert their therapeutic benefit for OCD
(Dougherty et al., 2004; Ravindran, Jung & Ravindran,
2010; Thomsen, 1998), a timespan that is considered longer
than that for the treatment of depression (Dougherty et al.,
2004; Thomsen, 1998). Therefore, it is unlikely this medica-
tion had a significant effect in such a short timeframe. Al-
though a study by Bergeron et al. showed that sertraline had
an earlier onset of therapeutic effect than fluoxetine in treat-
ing OCD, the “earlier onset” was first evident at 12 weeks of
treatment (Bergeron et al., 2002), and may be due to the
much longer half-life of fluoxetine (Bergeron et al., 2002).
However, as SSRIs are considered the first line pharmaco-
logic agent for acute and maintenance OCD treatment,
sertraline was started at a low dose and titrated to 50 mg
early in Amy’s hospitalization, per recommendation to tar-
get a high therapeutic dose with titration limited by side ef-
fect profile (Dougherty et al., 2004). However, more re-
search is indicated to determine how soon therapeutic treat-
ment effects can be evident with SSRIs in the treatment of
childhood and adolescent OCD.
SUMMARY
We presented a case of extreme OCD in an adolescent that
required immediate treatment due to her critical medical
condition. As an SSRI would not have quick enough onset
and the patient was initially resistant to participating in CBT,
the patient was hospitalized and first started on liquid
risperidone. The inpatient hospitalization itself was likely to
be significant in producing a reduction in symptoms and im-
provement in functioning, with the drawback ensuring that
treatment gains hold after discharge. Secondary to their
serotonergic and possibly anti-dopaminergic properties,
atypical antipsychotics may be useful for severe cases of
OCD which require a quicker onset of action than SSRIs
would allow for. Furthermore, antipsychotics may be an al-
ternative to benzodiazepines when a quicker anxiolytic ef-
fect is needed but issues of dependence, disinhibition or se-
dation are of concern. Atypical antipsychotics may also be
more protective of co-morbid mood disorders than ben-
zodiazepines.
The potential benefits of antipsychotics in treating anxi-
ety disorders must be balanced with their well-known poten-
tial side effects, including akathisia, extrapyramidal symp-
toms, weight gain, metabolic syndrome, and the fact that
very little is known regarding the effects of antipsychotics
on the developing brain (Gao et al., 2006). More research is
needed to determine the efficacy, safety, and tolerability of
atypical antipsychotics as an initial treatment choice for
OCD and other anxiety disorders in children and adoles-
cents. Sertraline is an FDA-approved treatment for child-
hood and adolescent OCD, but most data indicate that 6–12
weeks are needed to see benefit.
REFERENCES
APA (2000). Diagnostic and statistical manual of mental disorders
(4th ed., text rev.). Washington, DC: Author.
Attard, A., Ranjith, G. & Taylor, D. (2008). Delirium and its treat-
ment. CNS Drugs, 22, 631–644.
Bellino, S., Patria, L., Ziero, S. & Bogetto, F. (2005). Clinical pic-
ture of obsessive–compulsive disorder with poor insight: A re-
gression model. Psychiatry Research, 136, 223–231.
Bergeron, R., Ravindran, A. V., Chaput, Y., Goldner, E., Swinson,
R., van Ameringen, M. A., Austin, C. & Hadrava, V. (2002).
Sertraline and fluoxetine treatment of obsessive–compulsive
disorder: Results of a double-blind, 6-month treatment study.
Journal of Clinical Psychopharmacology, 22(2), 148–154.
Biederman, J. (1990). The diagnosis and treatment of adolescent
anxiety disorders. Journal of Clinical Psychiatry, 51 (Suppl
20-6), 50–53.
Björgvinsson, T., Wetterneck, C. T., Powell, D. M., Chasson, G.
S., Webb, S. A., Hart, J., Heffelfinger, S., Azzouz, R., Entricht,
T. L., Davidson, J. E. & Stanley, M. A. (2008). Treatment out-
come for adolescent obsessive–compulsive disorder in a spe-
cialized hospital setting. Journal of Psychiatric Practice, 14,
137–145.
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric,
V., Bracken, M. B. & Leckman, J. F. (2006). A systematic re-
view: Antipsychotic augmentation with treatment refractory
obsessive–compulsive disorder. Molecular Psychiatry, 11(7),
622–632.
Bodkin, J. A. & White, K. (1989). Clonazepam in the treatment of
obsessive–compulsive disorder associated with panic disorder
in one patient. Journal of Clinical Psychiatry, 50, 265–266.
Crockett, B. A., Churchill, E. & Davidson, J. R. (2004). A dou-
ble-blind combination study of clonazepam with sertraline for
obsessive–compulsive disorder. Annals of Clinical Psychiatry,
16, 127–132.
Decloedt, E. H. & Stein, D. J. (2010). Current trends in drug treat-
ment of obsessive–compulsive disorder. Neuropsychiatric
Disease and Treatment, 6, 233–242.
Denys, D., Zohar, J. & Westenberg, H. G. (2004). The role of dopa-
mine in obsessive–compulsive disorder: Preclinical and clini-
cal evidence. Journal of Clinical Psychiatry, 65 (Suppl 14),
11–17.
Dougherty, D. D., Rauch, S. L. & Jenike, M. A. (2004).
Pharmacotherapy for obsessive–compulsive disorder. J. Clin.
Psychol., 60(11), 1195–1202.
Gao, K., Muzina, D., Gajwani, P. & Calabrese, J. R. (2006). Effi-
cacy of typical and atypical antipsychotics for primary and
comorbid anxiety symptoms or disorders: A review. Journal of
Clinical Psychiatry, 67, 1327–1340.
Goldstein, R. B., Storch, E. A., Lehmkuhl, H., Geffken, G. R.,
Goodman, W. K. & Murphy, T. K. (2009). Successful medica-
tion withdrawal after cognitive-behavioral therapy in a treat-
ment-resistant preadolescent male with obsessive–compulsive
disorder. Depression and Anxiety, 26, E23–E25.
Grados, M. A. & Riddle, M. A. (2001). Pharmacological treatment
of childhood obsessive–compulsive disorder: From theory to
practice. Journal of Clinical Child Psychology, 30, 67–79.
Hollander, E., Kaplan, A. & Stahl, S. M. (2003). A double-blind,
placebo-controlled trial of clonazepam in obsessive–compul-
sive disorder. World Journal of Biological Psychiatry, 4,
30–34.
Ipser, J. C., Stein, D. J., Hawkridge, S. & Hoppe, L. (2009).
Pharmacotherapy for anxiety disorders in children and adoles-
cents. Cochrane Database of Systematic Reviews, July 8
2009(3), CD005170.
Kozak, M. J. & Foa, E. B. (1994). Obsessions, overvalued ideas,
and delusions in obsessive–compulsive disorder. Behaviour
Research and Therapy, 32, 343–353.
Lorenz, R. A., Jackson, C. W. & Saitz, M. (2010). Adjunctive use
of atypical antipsychotics for treatment-resistant generalized
anxiety disorder. Pharmacotherapy, 30, 942–951.
Masi, G., Millepiedi, S., Perugi, G., Pfanner, C., Berloffa, S., Pari,
C. & Mucci, M. (2009). Pharmacotherapy in paediatric obses-
sive–compulsive disorder: A naturalistic, retrospective study.
CNS Drugs, 23, 241–252.
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S. &
Price, L. H. (2000). A double-blind, placebo-controlled study
of risperidone addition in serotonin reuptake inhibitor-refrac-
tory obsessive–compulsive disorder. Archives of General Psy-
chiatry, 57, 794–801.
Mendels, J., Krajewski, T. F., Huffer, V., Taylor, R. J., Secunda, S.,
Schless, A., Sebastian, J. A., Semchyshyn, G., Durr, M. J.,
Melmed, A. S. & Whyte, A. (1986). Effective short-term treat-
ment of generalized anxiety disorder with trifluoperazine.
Journal of Clinical Psychiatry, 47, 170–174.
Nash, J. R. & Nutt, D. J. (2005). Pharmacotherapy of anxiety.
Handbook of Experimental Pharmacology, 169, 469–501.
Niendam, T. A., Berzak, J., Cannon, T. D. & Bearden, C. E. (2009).
Obsessive compulsive symptoms in the psychosis prodrome:
Correlates of clinical and functional outcome. Schizophrenia
Research, 108, 170–175.
Otto, M. W., Bruce, S. E. & Deckersbach, T. (2005). Benzodiaz-
epine use, cognitive impairment, and cognitive-behavioral
therapy for anxiety disorders: Issues in the treatment of a pa-
tient in need. Journal of Clinical Psychiatry, 66(Suppl 2),
34–38.
Perez de la Mora, M., Gallegos-Cari, A., Arizmendi-Garcia, Y.,
Marcellino, D. & Fuxe, K. (2010). Role of dopamine receptor
mechanisms in the amygdaloid modulation of fear and anxiety:
Structural and functional analysis. Progress in Neurobiology,
90, 198–216.
Pezze, M. A. & Feldon, J. (2004). Mesolimbic dopaminergic path-
ways in fear conditioning. Progress in Neurobiology, 74,
301–320.
POTS (2004). Cognitive-behavior therapy, sertraline, and their
combination for children and adolescents with obsessive–com-
pulsive disorder. Journal of the American Medical Associa-
tion, 292, 1969–1976.
Ravindran, L. N., Jung, S. M. & Ravindran, A. V. (2010). Intrave-
nous anti-obsessive agents: A review. Journal of Psycho-
pharmacology, 24, 287–296.
Reinblatt, S. P. & Walkup, J. T. (2005). Psychopharmacologic
treatment of pediatric anxiety disorders. Child and Adolescent
Psychiatric Clinics of North America, 14, 877–908.
Rodowski, M. F., Cagande, C. C. & Riddle, M. A. (2008). Child-
hood obsessive–compulsive disorder presenting as schizophre-
nia spectrum disorders. Journal of Child and Adolescent
Psychopharmacology, 18, 395–401.
Scahill, L., Walker, R. D., Lechner, S. N. & Tynan, K. E. (1993).
Inpatient treatment of obsessive–compulsive disorder in child-
hood: A case study. J. Child. Adolesc. Psychiatr. Ment. Health
Nurs., 6(3), 5–14.
Shoval, G., Zalsman, G., Sher, L., Apter, A. & Weizman, A.
(2006). Clinical characteristics of inpatient adolescents with
severe obsessive–compulsive disorder. Depression and Anxi-
ety, 23, 62–70.
Simeon, J. G. & Ferguson, H. B. (1987). Alprazolam effects in
children with anxiety disorders. Canadian Journal of Psychia-
try, 32, 570–574.
Tesar, G. E. & Jenike, M. A. (1984). Alprazolam as treatment for a
case of obsessive–compulsive disorder. American Journal of
Psychiatry, 141, 689–690.
Thomsen, P. H. (1998). Obsessive–compulsive disorder in children
and adolescents: Clinical guidelines. European Child and Ado-
lescent Psychiatry, 7, 1–11.
Thomsen, P. H. (2004). Risperidone augmentation in the treatment
of severe adolescent OCD in SSRI-refractory cases: A case se-
ries. Annals of Clinical Psychiatry, 16, 201–207.
Tumkaya, S., Karadag, F., Oguzhanoglu, N. K., Tekkanat, C.,
Varma, G., Ozdel, O. et al. (2009). Schizophrenia with obses-
sive–compulsive disorder and obsessive–compulsive disorder
with poor insight: A neuropsychological comparison. Psychia-
try Research, 165, 38–46.
Westenberg, H. G. M., Fineberg, N. A. & Denys, D. (2007).
Neurobiology of obsessive–compulsive disorder: Serotonin
and beyond. CNS Spectrums, 12(2)(Suppl 3), 14–27.
Westra, H. A., Stewart, S. H. & Conrad, B. E. (2002). Naturalistic
manner of benzodiazepine use and cognitive behavioral ther-
apy outcome in panic disorder with agoraphobia. Journal of
Anxiety Disorders, 16, 233–246.
Witek, M. W., Rojas, V., Alonso, C., Minami, H. & Silva, R. R.
(2005). Review of benzodiazepine use in children and adoles-
cents. Psychiatric Quarterly, 76, 283–296.
82 | Journal of Behavioral Addictions 1(2), pp. 78–82 (2012)
Nguyen et al.
